Backgrounds/Aims: We performed a retrospective, single-center cohort study to evaluate the impact of various treatment modalities and recent changes in treatment modalities, including the increased application of chemotherapy, on survival in patients with pancreatic cancer. Methods: All patients with pancreatic cancer who were diagnosed and treated at Seoul National University Hospital between January 2007 and December 2014 were registered in a prospective clinical database and included in this retrospective study. All patients' radiologic imaging diagnoses were re-reviewed according to the National Cancer Center Network guidelines. The patients were divided into four groups according to their clinical stage, and each clinical stage group was further divided into four groups according to treatment modality. Results: Overall, 475 (28.9%) patients had resectable pancreatic cancer, 129 (7.8%) patients borderline resectable pancreatic cancer, 384 (23.3%) patients locally advanced pancreatic cancer, and 658 (40.0%) patients metastatic pancreatic cancer. Among the patients with borderline resectable pancreatic cancer, the median survival was significantly longer in the neoadjuvant therapy (NAT)+surgery groups (24 months) than the surgery without NAT (16 months) group (p=0.049). A multivariate survival analysis revealed that compared with the surgery group, the 5-year mortality risk was decreased by 35% in the NAT+surgery group (24 vs. 20 months, p=0.045). Conclusions: This retrospective cohort study showed that the rates of resectable and surgically treatable pancreatic cancer were 29.1% and 32.2%, which are higher than those reported previously, and aggressive NAT for select advanced-stage patients could lead to better survival outcomes. (Ann Hepatobiliary Pancreat Surg 2018;22:386-396)
INTRODUCTION
Despite improvements in perioperative outcomes, pancreatic cancer has a poor prognosis, with a 5-year survival rate of only 8%-10% among patients. 1, 2 Most patients are diagnosed in the advanced stages, and effective systemic therapies are lacking. According to the annual report of cancer statistics in Korea, the 5-year survival rate of overall pancreatic cancer patients was 10% in 2014, with the higher rate due to increased early diagnoses following the introduction of a routine cancer screening program for all citizens conducted by the National Health Insurance, and increased detection of less aggressive pancreatic malignancies. 3 In addition, effective systemic treatments including neoadjuvant therapies (NATs) have been introduced in an attempt to overcome the limitations of prior treatments and to improve patient outcomes, especially in patients with borderline resectable, locally advanced, and even metastatic pancreatic cancer; therefore, the outcomes of pancreatic cancer patients have been improved by additional surgical resection after systemic treatment. [4] [5] [6] However, because the definitions of borderline resectable and locally advanced pancreatic cancer differ among institutions, it is impossible to compare survival rates according to clinical stage in pancreatic cancer patients. In addition, the data published by most institutions do not Table 1 . The National Comprehensive Cancer Network definitions for the CT-based staging of pancreatic cancer Resectable Tumor-artery relationship: no radiographic evidence of arterial abutment (celiac, SMA, or hepatic artery) Tumor-vein relationship: tumor-induced narrowing, if present, is ≤50% of the circumference of the SMV, PV, or SMV-PV confluence Borderline resectable Artery: tumor abutment (≤180° of the circumference) of SMA or celiac artery. Tumor abutment or short segment encasement (＞180°) of the common hepatic artery. Tumor abutment ＞180° without involvement of the aorta and amenable to celiac resection (HA-GDA not involved) Vein: Tumor induced narrowing of ＞50 % of SMV, PV, or SMV-PV, or short segment occlusion of SMV, PV, SMV-PV with suitable PV (above) and SMV (below) to allow for safe vascular reconstruction.
Locally advanced
Artery: tumor encasement (＞180° of the circumference) of SMA or celiac artery Vein (SM-PV confluence): occlusion of SMV, PV, or SMV-PV without suitable vessels above and below the tumor to allow for reconstruction (no distal or proximal target for vascular reconstruction) 
MATERIALS AND METHODS

Database
We conducted a retrospective cohort study using prospectively recorded information of patients registered in a clinical oncology database at Seoul National University (a tumor marker; normal range ＜37 U/ml), and pathologic reports were extracted from the medical records.
11
We re-reviewed the images of computed tomography and The TNM residual tumor classification was recorded in patients who underwent pancreatectomy with curative intent. 13 We used the tumor regression grading system of We also conducted multivariate analysis using the Cox proportional hazards model to determine prognostic factors for survival in patients with pancreatic cancer. The results showed surgery after NAT compared with surgery or CTx alone, female sex, resectable stage, a CA 19-9 level within the normal range at diagnosis, and tumor location in the pancreatic body or tail to be prognostic factors for improved survival in patients with pancreatic cancer.
Prognostic factors for survival according to clinical stage
Tzeng et al. also reported that serum CA 19-9 is a dynam-ic preoperative marker of tumor biology and the response to NAT, and provides prognostic information in patients with unresected or resected BRPC. 20 In addition, another study revealed that patients with advanced pancreatic cancer whose serum tumor marker levels had normalized after NAT may be appropriate candidates for tumor resection. 25 Some strengths and limitations of this study also warrant discussion. First, because this was a retrospective analysis of patients treated at a single institution, the results are subject to the biases and limitations inherent to retrospective studies. Nevertheless, this is one of the largest reported cohorts of patients with resectable, borderline resectable, locally advanced, or metastatic pancreatic cancer in which the cancer was staged using objective radiographic criteria and classified using consensus guidelines.
Second, we divided the patients into four groups based on their treatment modalities. Unfortunately, the numbers of patients varied among the groups, with some groups being too small for detailed analyses. As a result of ethical issues and difficulty in recruiting patients, no random- further insight into the benefits of NAT. 19, [26] [27] [28] Third, this study included heterogenous regimens of NAT, which showed different oncologic outcomes.
In conclusion, based on the results of this retrospective, single-center, large cohort study, categorizing all pancreatic cancer patients according to clinical stage using uniform imaging diagnostic criteria with high-resolution images, the rates of resectable and surgically treatable pancreatic cancer were 29.1% and 32.2%, which are higher than those reported previously. In the RPC group, 434 (91.4%) patients underwent surgery, and R0 resection was achieved in 388 (81.0%). Although our findings support the use of NAT in eligible patients with borderline resectable pancreatic cancer, the survival rate of advanced-stage patients is still low; thus, more effective systemic therapies are required. In addition, further studies are needed to evaluate the effects of specific NAT regimens and to update consensus guidelines with biological features.
